Summary
This article discusses potential drug/disease interaction between the glucagon-like peptide-1 (GLP-1)-based diabetic therapies and pancreatitis (acute and chronic) and pancreatic cancer.
- Gastrointestinal Cancers
- Diabetes Mellitus
- Gastrointestinal Cancers
- Diabetes Mellitus
- Endocrinology
- Diabetes & Metabolic Syndrome
- © 2013 MD Conference Express®